PI3K pathway alterations, which are implicated in tumor survival, immune evasion, and therapeutic resistance, were slightly more prevalent in H/L patients (21.7%) compared to NHW patients (17.4%) (p = 0.4728). This evidence concerns the gene PIK3CB and neoplasm.